Exploiting the Nephrotoxic Effects of Venom from the Sea Anemone, Phyllodiscus semoni, to Create a Hemolytic Uremic Syndrome Model in the Rat
Open Access
- 23 July 2012
- journal article
- review article
- Published by MDPI AG in Marine Drugs
- Vol. 10 (7) , 1582-1604
Abstract
In the natural world, there are many creatures with venoms that have interesting and varied activities. Although the sea anemone, a member of the phylum Coelenterata, has venom that it uses to capture and immobilise small fishes and shrimp and for protection from predators, most sea anemones are harmless to man. However, a few species are highly toxic; some have venoms containing neurotoxins, recently suggested as potential immune-modulators for therapeutic application in immune diseases. Phyllodiscus semoni is a highly toxic sea anemone; the venom has multiple effects, including lethality, hemolysis and renal injuries. We previously reported that venom extracted from Phyllodiscus semoni induced acute glomerular endothelial injuries in rats resembling hemolytic uremic syndrome (HUS), accompanied with complement dysregulation in glomeruli and suggested that the model might be useful for analyses of pathology and development of therapeutic approaches in HUS. In this mini-review, we describe in detail the venom-induced acute renal injuries in rat and summarize how the venom of Phyllodiscus semoni could have potential as a tool for analyses of complement activation and therapeutic interventions in HUS.Keywords
This publication has 152 references indexed in Scilit:
- Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseasesToxicon, 2012
- Inhibition of voltage‐gated Na+ currents in sensory neurones by the sea anemone toxin APETx2British Journal of Pharmacology, 2011
- Design and Synthesis of (+)-Discodermolide–Paclitaxel Hybrids Leading to Enhanced Biological ActivityJournal of Medicinal Chemistry, 2011
- Atypical hemolytic uremic syndromeOrphanet Journal of Rare Diseases, 2011
- Reversal of acid‐induced and inflammatory pain by the selective ASIC3 inhibitor, APETx2British Journal of Pharmacology, 2010
- The anticancer effects of actinoporin RTX-A from the sea anemone Heteractis crispa (=Radianthus macrodactylus)Toxicon, 2010
- Humanized cobra venom factor decreases myocardial ischemia–reperfusion injuryMolecular Immunology, 2009
- ASIC3, a sensor of acidic and primary inflammatory painThe EMBO Journal, 2008
- Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndromeProceedings of the National Academy of Sciences, 2007
- Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeBlood, 2006